Autologous Anti-CD5 CAR Monocytes MT-101

Preferred Label : Autologous Anti-CD5 CAR Monocytes MT-101;

NCIt synonyms : mRNA-engineered CD5-CAR-M MT-101; mRNA-engineered CD5-CAR Monocyte MT-101; CD5 ATAK CAR Monocytes MT-101; Autologous Anti-CD5 CAR-M MT-101;

NCIt definition : A preparation of autologous monocytes genetically modified with mRNA technology to express a chimeric antigen receptor (CAR) specific for CD5, with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD5 CAR monocytes MT-101 specifically recognize and bind to CD5-expressing tumor cells, and expose the immune system to the CD5 glycoprotein. This may elicit a cytotoxic T-lymphocyte (CTL) response against CD5-expressing tumor cells. CD5 is a T-cell surface glycoprotein expressed on the surface of normal T-cells and overexpressed on various B- and T-cell malignancies.;

Molecule name : MT 101; MT-101;

NCI Metathesaurus CUI : CL1792221;

Details

Origin ID

C187269;

UMLS CUI

C5706388;

Semantic type(s)
- Cell [UMLS semantic type]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- T-Cell Surface Glycoprotein CD5 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients